LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-19 and is reviewed periodically as new material appears.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
In heterolytic cleavage, or heterolysis, the bond breaks in such a fashion that the originally-shared pair of electrons remain with one of the fragments. Thus, a fragment gains an electron, having both bonding electrons, while the other fragment loses an electron. This process is also known as ionic fission. The singlet excitation energy of a sigma bond is the energy required for heterolytic dissociation, but the actual singlet excitation energy may be lower than the bond-dissociation energy of heterolysis as a result of the Coulombic attraction between the two ion fragments. The singlet excitation energy of a silicon–silicon sigma bond is lower than the carbon–carbon sigma bond, even though their bond strengths are 327kJ/mol and 607kJ/mol[1] respectively, because silicon has higher electron affinity and lower ionization potential than carbon. Heterolysis occurs naturally in reactions that involve electron donor ligands and transition metals which have empty orbitals.
Ligamentous laxity or ligament laxity can appear in a variety of ways and levels of severity. In most people, ligaments (which are the tissues that connect bones to each other) are naturally tight in such a way that the joints are restricted to 'normal' ranges of motion. This creates normal joint stability. If muscular control does not compensate for ligamentous laxity, joint instability may result. The trait is almost certainly hereditary, and is usually something the affected person would just be aware of, rather than a serious medical condition. However, if there is widespread laxity of other connective tissue, then this may be a sign of Ehlers–Danlos syndrome, Down syndrome, Klippel–Feil syndrome, juvenile idiopathic arthritis, Larsen syndrome, Marfan syndrome, osteogenesis imperfecta, and other medical conditions. Ligamentous laxity may also result from injury, such as from a vehicle accident. It can result from whiplash and be overlooked for years by doctors who are not looking for it, despite the chronic pain that accompanies the resultant spinal instability. Ligamentous laxity will show up on an upright magnetic resonance imaging (MRI), the only kind of MRI that will show soft tissue damage. It can only be inferred from a digital motion x-ray.
There were no requirements for bioequivalence in generic medications in China until the 2016 Opinion on Conducting Consistent Evaluation of the Quality and Efficacy of Generic Drugs (关于开展仿制药质量和疗效一致性评价的意见), which established basic rules for future bioequivalence work. Since July 2020, all newly approved generics must pass bioequivalence checks; previous drugs may apply to be checked. Since 2019, National Centralized Volume-Based Procurement uses "passes generic-consistency evalulation" as one of the bidding criteria. The Chinese definition of "bioequivalence" entails having the test drug's geometric mean Cmax, AUC(0–t), and AUC(0–∞) fall into 80%–125% of the reference drug in both fasting and fed states. The reference drug should be preferably the original brand-name drug, then (if not available) an internationally recognized generic approved by a developed country, then (if still not available) an internationally recognized generic approved domestically – this is to avoid deviation from the original drug by serial use of generics as reference. If pharmacokinetic values such as Cmax do not apply to the type of drug (e.g. if the drug is not absorbed orally), comparisons can be made using other means such as dose-response curves. According to Wei et al. (2022), the Consistency Evaluation Policy increased R&D spending for Chinese pharmaceutical companies, especially among private and high-yielding ones. Liu et al. (2023) argues that the Policy increased the innovation quality of the Chinese pharmaceutical industry.
Sources: en.wikipedia.org
=== Pharmacodynamics === Leucine is a dietary amino acid with the capacity to directly stimulate myofibrillar muscle protein synthesis. This effect of leucine results from its role as an activator of the mechanistic target of rapamycin (mTOR), a serine-threonine protein kinase that regulates protein biosynthesis and cell growth. The activation of mTOR by leucine is mediated through Rag GTPases, leucine binding to leucyl-tRNA synthetase, leucine binding to sestrin 2, and possibly other mechanisms.
Many gas chromatograph detectors are ion detectors with varying methods of ionizing the components eluting from the gas chromatograph's column. An ion detector is analogous to a capacitor or vacuum tube. It can be envisioned as two metal grids separated by air with inverse charges placed on them. An electric potential difference (voltage) exists between the two grids. After components are ionized in the detector, they enter the region between the two grids, causing current to pass from one to the other. This current is amplified and is the signal generated by the detector. The higher the concentration of the component, the more ions are generated, and the greater the current. Some early FIDs actually used two metal grids as their ion detectors. However, more efficient designs have been developed, so few current ion-type detectors use two metal grids. But the principle is the same, and it can be easiest to think of the detector in this manner.
Shortly after the show-cause notices were issued, Essendon and James Hird challenged the legal validity of the joint investigation that ASADA had conducted with the AFL, temporarily putting the notices on hold. The club argued that although AFL rules allowed it to compel its players and officials to be interviewed, ASADA had no legal right to do the same – and therefore that evidence collected by the AFL in a compulsory interview was inadmissible for an ASADA investigation. The case came before the Melbourne division of the Federal Court of Australia on 27 June 2014; and on 19 September 2014, Justice John Middleton of the Federal Court dismissed the challenge and found investigation to be lawful. In the decision, he ruled that ASADA had actively used the AFL's power to compel interviews to overcome its own inability to do likewise; but, that this was within the rule of law and with the Essendon players' knowledge, because all interviews were knowingly held in the presence of an ASADA representative. On 1 October 2014, Essendon announced that it would not appeal the ruling, stating that to do so would act against the interests of the players. Hird, however, acting in an individual capacity and "on a matter of principle", appealed the ruling to a full bench of the Federal Court. Media commentators speculated that Hird's action would result in his termination as Essendon coach, and Hird himself later testified in court that he had been advised as much, but this did not occur and he remained to coach in 2015.
=== Gene therapy === Gene therapy is a therapeutic approach that involves modifying or replacing faulty genes to treat or prevent diseases. In theranostics, gene therapy can be combined with diagnostic imaging to monitor the delivery, expression, and activity of therapeutic genes. Imaging techniques such as MRI, PET, and optical imaging enable non-invasive assessment of gene transfer and expression, providing valuable insights into the efficacy and safety of gene-based treatments. Gene therapy has shown potential in treating genetic disorders, cancer, and cardiovascular diseases, and its integration with diagnostic imaging offers a comprehensive approach for monitoring and optimizing treatment outcomes.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.